We next validated the beneficial effect of PIK3CA mutations compared with seed mutations of LRP1B and AHNAK2 in another dataset containing 40% of samples from the overall STAD patient (Supplementary Fig. 3A-3B). This evidence concerns the gene AHNAK2 and gastric adenocarcinoma.